Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02187224 · ClinicalTrials.gov registry record · Phase 2
Progesterone Effect on Individuals Diagnoses With AD and PTSD.
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT02187224 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 13 participants.
The verdict
NCT02187224, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a randomized control trial with an anticipated 36 participants diagnosed with post-traumatic stress disorder (PTSD) and comorbid alcohol dependence. Participants will be randomized to receive either progesterone (200 mg. bid) or placebo in identical looking capsules for three days. One goal of this research study is to test if progesterone is more effective than placebo in reducing craving after exposure to trauma cues and alcohol cues in a laboratory paradigm among men and women with AD and PTSD. We hypothesize that progesterone in comparison to placebo will significantly reduce craving for alcohol in response to trauma cues alone and in combination with alcohol cues in individuals with AD and PTSD. A second goal is to examine if there are gender differences in progesterone effects on stress and alcohol cue-induced craving. We hypothesize that the effects of progesterone on stress and craving will be stronger in women than in men. Participants will be recruited primarily through advertisement, but also through the clinical facilities at the VA and from other collaborators.
Interventions
- DRUG Progesterone
- DRUG Placebo (for Progesterone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2021-09-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02187224
The ClinicalTrials.gov registry entry for NCT02187224 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Progesterone is the first listed.
NCT02187224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02187224 about?
NCT02187224 is a clinical study titled "Progesterone Effect on Individuals Diagnoses With AD and PTSD.". This is a randomized control trial with an anticipated 36 participants diagnosed with post-traumatic stress disorder (PTSD) and comorbid alcohol dependence. Participants will be randomized to receive either progesterone (200 mg. bid) or placebo in identical looking capsules for three days. One goal...
What is the current status of trial NCT02187224?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2016-09-01. Estimated completion is 2021-09-08.
What interventions are being tested in trial NCT02187224?
The interventions under investigation include: Progesterone (DRUG), Placebo (for Progesterone) (DRUG).
Who is sponsoring clinical trial NCT02187224?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.